🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524468-40-00
Ongoing Phase I

A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)

2025-524468-40-00 · tracked via the Priya Life Science EU tracker
Sponsor
Universitaetsklinikum Erlangen AöR
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Immune System Diseases
Decision date
27/03/2026
Enrollment target
14
Sites
Germany

Condition studied

chronic Graft-versus-Host-Disease (cGvHD)

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524468-40-00 on CTIS ↗ ← All trials in the EU